BrainsWay Presents New Data on Deep TMS for PTSD and Depression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
BrainsWay announced the presentation of new real-world data demonstrating significant improvements in patients with comorbid post-traumatic stress disorder and Major Depressive Disorder treated with Deep Transcranial Magnetic Stimulation. This real-world data collection study evaluated the efficacy of Deep TMS as a tool to improve both PTSD and MDD symptoms in patients with comorbid disease. All 462 patients in the retrospective study, from 11 clinical sites, were diagnosed with both MDD and PTSD, received at least 20 Deep TMS treatment sessions using BrainsWay's H1 or H7 coils. Outcomes included changes in the PTSD Checklist for DSM-5 and the Patient Health Questionnaire-9 before and after treatment. Of these patients, 83.5% experienced a response, with an average 52% reduction in PCL-5 scores. Patients also experienced substantial improvements in depression symptoms, including a 66.6% response rate, a 27.3% remission rate, and an average 50% reduction in PHQ-9 scores.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BWAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BWAY
Wall Street analysts forecast BWAY stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.020
Low
19.00
Averages
26.33
High
30.00
Current: 16.020
Low
19.00
Averages
26.33
High
30.00
About BWAY
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BrainsWay Presents Positive Data on PTSD and Depression Treatment
- Significant Research Findings: Among 462 patients diagnosed with both PTSD and Major Depressive Disorder, 83.5% experienced a reduction of over 50% in PTSD symptoms after Deep TMS treatment, with an average reduction of 52%, demonstrating the efficacy of Deep TMS in complex psychiatric disorders.
- Notable Depression Improvement: Following Deep TMS treatment, the response rate for depression symptoms reached 66.6%, with 27.3% of patients achieving remission and an average 50% reduction in PHQ-9 scores, indicating the treatment's potential for depression management.
- Clinical Data Support: This study represents the largest real-world analysis of Deep TMS in patients with comorbid PTSD and Major Depressive Disorder to date, further solidifying the application prospects of Deep TMS in mental health.
- Future Development Direction: Although Deep TMS is not yet FDA-cleared for the treatment of PTSD and its comorbidities, the study results provide strong support for its potential as a treatment option, and BrainsWay will continue to advance related clinical research and technology development.
See More
BrainsWay Expands TMS Coverage Policies Across U.S.
- Policy Expansion: BrainsWay announced an expansion of medical policies in the U.S., covering 2 million members in South Carolina for its SWIFT™ Accelerated Deep TMS™ protocol, indicating a growing influence in the mental health sector.
- Increased Coverage Population: Eight major payers and the U.S. Department of Veterans Affairs now support accelerated TMS treatments, covering over 57 million lives, reflecting a rising acceptance and recognition of Deep TMS therapies.
- Clinical Evidence Support: CEO Hadar Levy emphasized that the company's ongoing clinical research consistently demonstrates the efficacy of Deep TMS across various indications, particularly for depression and OCD, driving demand for innovative therapies among patients.
- Future Development Focus: BrainsWay plans to advance additional coverage opportunities and is committed to enhancing patient access to evidence-based neurostimulation treatments through scientific research and policy collaboration, enabling more patients to benefit from its innovative therapies.
See More
BrainsWay Presents New Durability Data for Deep TMS in Depression Treatment
- Durability of Clinical Effects: BrainsWay's presentation at the 2026 Clinical TMS Society meeting revealed that over 80% of patients with Major Depressive Disorder maintained remission at the 12-month follow-up after receiving the SWIFT™ Deep TMS treatment, demonstrating the long-term efficacy of this technology and significant improvements in patients' quality of life.
- Significant Functional Improvement: Among patients treated with the SWIFT™ protocol, the percentage of those with severe functional impairment dropped from 85% at baseline to 0%, reflecting not only the positive impact on work performance and social engagement but also the potential of Deep TMS technology to enhance overall patient well-being.
- Reduced Medication Dependency: During the 12-month observation period, less than 25% of patients receiving the SWIFT™ treatment required changes in their prescribed medication or additional TMS treatments, indicating the stability and effectiveness of this treatment approach while reducing patients' reliance on medication.
- Innovative Treatment Protocol: This study is the first prospective randomized controlled trial to evaluate the one-year durability of both conventional and accelerated Deep TMS treatments, marking a new era in depression treatment and providing more options for patients and providers, further validating BrainsWay's commitment to innovation in mental healthcare.
See More
BrainsWay Enters Strategic Equity Financing Agreement with Hopemark
- Strategic Investment: BrainsWay has entered into a strategic equity financing agreement with Hopemark, initially investing $1.5 million with the potential for an additional $1.5 million based on milestones, aimed at enhancing access to and awareness of mental health treatments.
- Partnership Outlook: CEO Hadar Levy stated that this investment will allow BrainsWay to focus on advancing its business and technology while partnering with growth-oriented clinical platforms to enhance its market position.
- Hopemark's Strengths: Hopemark CEO Abid Nazeer emphasized that BrainsWay's investment not only provides growth capital but also brings a deep understanding of interventional psychiatry, aiding Hopemark in scaling efficiently and improving patient outcomes.
- Industry Impact: This collaboration signifies BrainsWay's further commitment to the mental health sector, expected to accelerate the application and market penetration of Deep TMS technology, driving overall business growth.
See More
BrainsWay Ltd Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 35% increase in revenue to $15.5 million for Q1 2026, indicating strong demand and sustained growth potential in the deep TMS market.
- Continued Profitability Improvement: The company achieved its 11th consecutive quarter of profitability with net income exceeding $2.3 million, more than doubling year-over-year, reflecting the effectiveness of its business model and increased market acceptance.
- Accelerated Market Expansion: The company shipped 117 deep TMS systems in the quarter, a 44% increase year-over-year, expanding its total install base to approximately 1,820 systems, thereby solidifying its market position in mental health.
- Increased R&D and Marketing Investment: Despite rising sales and marketing expenses to $4.9 million and R&D expenses to $2.8 million, these investments are expected to drive future product innovation and market expansion, supporting the company's long-term growth strategy.
See More
BrainsWay Q1 Earnings Beat Expectations with Strong Guidance
- Strong Earnings Report: BrainsWay reported Q1 GAAP EPS of $0.06, beating expectations by $0.01, indicating sustained profitability and enhancing its competitive position in the market.
- Significant Revenue Growth: The company achieved Q1 revenue of $15.53 million, a 34.6% year-over-year increase, exceeding market expectations by $0.91 million, reflecting robust product demand and expanding market share.
- 2026 Financial Guidance: BrainsWay reiterated its full-year 2026 revenue guidance of $66 million to $68 million, representing a growth of 27% to 30% compared to 2025, showcasing confidence in future growth prospects.
- Profitability Outlook: The company anticipates operating income to be 13% to 14% of revenue, with adjusted EBITDA expected to range from $12 million to $14 million, indicating an anticipated growth of 86% to 100% over 2025, further solidifying its financial health.
See More
BrainsWay Presents Positive Data on PTSD and Depression Treatment
- Significant Research Findings: Among 462 patients diagnosed with both PTSD and Major Depressive Disorder, 83.5% experienced a reduction of over 50% in PTSD symptoms after Deep TMS treatment, with an average reduction of 52%, demonstrating the efficacy of Deep TMS in complex psychiatric disorders.
- Notable Depression Improvement: Following Deep TMS treatment, the response rate for depression symptoms reached 66.6%, with 27.3% of patients achieving remission and an average 50% reduction in PHQ-9 scores, indicating the treatment's potential for depression management.
- Clinical Data Support: This study represents the largest real-world analysis of Deep TMS in patients with comorbid PTSD and Major Depressive Disorder to date, further solidifying the application prospects of Deep TMS in mental health.
- Future Development Direction: Although Deep TMS is not yet FDA-cleared for the treatment of PTSD and its comorbidities, the study results provide strong support for its potential as a treatment option, and BrainsWay will continue to advance related clinical research and technology development.
See More
BrainsWay Expands TMS Coverage Policies Across U.S.
- Policy Expansion: BrainsWay announced an expansion of medical policies in the U.S., covering 2 million members in South Carolina for its SWIFT™ Accelerated Deep TMS™ protocol, indicating a growing influence in the mental health sector.
- Increased Coverage Population: Eight major payers and the U.S. Department of Veterans Affairs now support accelerated TMS treatments, covering over 57 million lives, reflecting a rising acceptance and recognition of Deep TMS therapies.
- Clinical Evidence Support: CEO Hadar Levy emphasized that the company's ongoing clinical research consistently demonstrates the efficacy of Deep TMS across various indications, particularly for depression and OCD, driving demand for innovative therapies among patients.
- Future Development Focus: BrainsWay plans to advance additional coverage opportunities and is committed to enhancing patient access to evidence-based neurostimulation treatments through scientific research and policy collaboration, enabling more patients to benefit from its innovative therapies.
See More
BrainsWay Presents New Durability Data for Deep TMS in Depression Treatment
- Durability of Clinical Effects: BrainsWay's presentation at the 2026 Clinical TMS Society meeting revealed that over 80% of patients with Major Depressive Disorder maintained remission at the 12-month follow-up after receiving the SWIFT™ Deep TMS treatment, demonstrating the long-term efficacy of this technology and significant improvements in patients' quality of life.
- Significant Functional Improvement: Among patients treated with the SWIFT™ protocol, the percentage of those with severe functional impairment dropped from 85% at baseline to 0%, reflecting not only the positive impact on work performance and social engagement but also the potential of Deep TMS technology to enhance overall patient well-being.
- Reduced Medication Dependency: During the 12-month observation period, less than 25% of patients receiving the SWIFT™ treatment required changes in their prescribed medication or additional TMS treatments, indicating the stability and effectiveness of this treatment approach while reducing patients' reliance on medication.
- Innovative Treatment Protocol: This study is the first prospective randomized controlled trial to evaluate the one-year durability of both conventional and accelerated Deep TMS treatments, marking a new era in depression treatment and providing more options for patients and providers, further validating BrainsWay's commitment to innovation in mental healthcare.
See More
BrainsWay Enters Strategic Equity Financing Agreement with Hopemark
- Strategic Investment: BrainsWay has entered into a strategic equity financing agreement with Hopemark, initially investing $1.5 million with the potential for an additional $1.5 million based on milestones, aimed at enhancing access to and awareness of mental health treatments.
- Partnership Outlook: CEO Hadar Levy stated that this investment will allow BrainsWay to focus on advancing its business and technology while partnering with growth-oriented clinical platforms to enhance its market position.
- Hopemark's Strengths: Hopemark CEO Abid Nazeer emphasized that BrainsWay's investment not only provides growth capital but also brings a deep understanding of interventional psychiatry, aiding Hopemark in scaling efficiently and improving patient outcomes.
- Industry Impact: This collaboration signifies BrainsWay's further commitment to the mental health sector, expected to accelerate the application and market penetration of Deep TMS technology, driving overall business growth.
See More
BrainsWay Ltd Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 35% increase in revenue to $15.5 million for Q1 2026, indicating strong demand and sustained growth potential in the deep TMS market.
- Continued Profitability Improvement: The company achieved its 11th consecutive quarter of profitability with net income exceeding $2.3 million, more than doubling year-over-year, reflecting the effectiveness of its business model and increased market acceptance.
- Accelerated Market Expansion: The company shipped 117 deep TMS systems in the quarter, a 44% increase year-over-year, expanding its total install base to approximately 1,820 systems, thereby solidifying its market position in mental health.
- Increased R&D and Marketing Investment: Despite rising sales and marketing expenses to $4.9 million and R&D expenses to $2.8 million, these investments are expected to drive future product innovation and market expansion, supporting the company's long-term growth strategy.
See More
BrainsWay Q1 Earnings Beat Expectations with Strong Guidance
- Strong Earnings Report: BrainsWay reported Q1 GAAP EPS of $0.06, beating expectations by $0.01, indicating sustained profitability and enhancing its competitive position in the market.
- Significant Revenue Growth: The company achieved Q1 revenue of $15.53 million, a 34.6% year-over-year increase, exceeding market expectations by $0.91 million, reflecting robust product demand and expanding market share.
- 2026 Financial Guidance: BrainsWay reiterated its full-year 2026 revenue guidance of $66 million to $68 million, representing a growth of 27% to 30% compared to 2025, showcasing confidence in future growth prospects.
- Profitability Outlook: The company anticipates operating income to be 13% to 14% of revenue, with adjusted EBITDA expected to range from $12 million to $14 million, indicating an anticipated growth of 86% to 100% over 2025, further solidifying its financial health.
See More
